Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5541664 | 0.84 | CXCR2 (0.38) | SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL10953070 | 0.77 | CES2 (0.33) | — | |
| SCHEMBL11687745 | 0.75 | MCHR1 (0.42) | SMN1; SMN2NPC1RAB9APOLBMAPK1 | |
| SCHEMBL2953965 | 0.75 | RAB9A (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1BACE1 | |
| SCHEMBL11791700 | 0.75 | HTR7 (0.47) | SMN1; SMN2RAB9AALDH1A1HSD17B10LMNA | |
| SCHEMBL7699313 | 0.75 | DBH (0.37) | SMN1; SMN2NPC1RAB9AALDH1A1BACE1 | |
| SCHEMBL778637 | 0.75 | BACE1 (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1BACE1 | |
| SCHEMBL5546274 | 0.73 | CA2 (0.36) | ALDH1A1TP53LMNAL3MBTL1KMT2A | |
| SCHEMBL30784461 | 0.73 | BACE1 (0.45) | SMN1; SMN2NPC1RAB9AALDH1A1BACE1 | |
| SCHEMBL11356940 | 0.72 | SLC6A2 (0.39) | POLBMEN1KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-0334590-B1 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | LILLY CO ELI (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-0494118-B1 | Process for 3-exomethylenecepham sulfoxide esters | LILLY CO ELI (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5512454-A | Enzymatic acylation of 3-hydroxymethyl cephalosporins | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-30 | — | — | US | disclosed |
| EP-0677523-A1 | 3-(substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1995-10-18 | — | — | EP | disclosed |
| EP-0667396-A1 | Enzymatic acylation of 3-hydroxymethyl cephalosporins | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
| US-4855418-A | Process for production of ceophalosporins | ELI LILLY AND COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| EP-0324562-A1 | 1-Carba(dethia)-3-cephem derivatives | ELI LILLY AND COMPANY (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4820816-A | 3-trifuoromethylsulfonyloxy-substituted 1-carbacephalosporins as intermediates for antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1989-04-11 | — | — | US | disclosed |
| US-4820832-A | Process for preparing 3-unsubstituted cephalosporins and 1-carba(dethia)cephalosporins | ELI LILLY AND COMPANY (US) | 1989-04-11 | — | — | US | disclosed |
| EP-0299728-A2 | Carbonylation process for beta-lactam antibiotics | ELI LILLY AND COMPANY (US) | 1989-01-18 | — | — | EP | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4778884-A | REACTING TRIFLUOROMETHYLSULFONYLOXY COMPOUND WITH LITHIUM HALIDE IN APROTIC POLAR SOLVENT | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1988-10-18 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4673737-A | ANTIBIOTICS/ | HARVARD UNIVERSITY (US) | 1987-06-16 | — | — | US | disclosed |
| EP-0211540-A1 | Intermediates and process for antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SMN1; SMN2 3985/4885NPC1 2404/4885RAB9A 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.